BibTex RIS Cite
Year 2016, Volume: 2 Issue: 1, 0 - 0, 27.03.2016

Abstract

References

  • Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11.
  • Harris JC. Disorders of Purine and Pyrimidine Metabolism. In:Kliegman RM, Behrman RE, editors. Nelson Textbook Of Pediatrics 19thed. Philadelphia, PA, USA:Elsevier Saunders; 2011. pp 516-517.
  • Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999;33:225-34.
  • Leusmann DB. A classification of urinary calculi with respect to their composition and micromorphology. Scand J Urol 1991;25:141–50.
  • Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences and treatment of tumor lysis syndrome. Am J Med 2004;116:546-54.
  • DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966;274:481-86.
  • Brogard JM, Coumaros D, Franckhauser J, Stahl A, Stahl J. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol 1972;17: 890-95.
  • Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21(23):4402-6.
  • Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B. et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19(3):697-704.
  • Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
  • Hobbs DJ, Steinke JM, Chung JY, Barletta GM, Bunchman TE. Rasburicase improves hyperuricemia in infants with acute kidney injury. Pediatr Nephrol 2010;25:305-9.
  • Murphy, JH. Nonimmune Hydrops Fetalis. NeoReviews 2004;5:e5-e14.
  • Bunchman TE, McBryde KD, Mottes TE, Gardner JJ, Maxvold NJ, Brophy PD. Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol 2001;16:1067-71.
  • Andreoli SP. Acute renal failure in the newborn. Semin Perinatol 2004;28:112-23.
  • Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk of kidney disease. J Am Soc Nephrol 2008;19:2407-13.
  • LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY, Moritz ML. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007;22:132-35.
  • Maisels MJ. Jaundice. In: S. M. MacDonald MG, Avery's Neonatology. 6thed. Lippincott Williams & Wilkins; 2005. pp: 768-90.

Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant

Year 2016, Volume: 2 Issue: 1, 0 - 0, 27.03.2016

Abstract

Akut böbrek yetmezliği ve tümör lizis sendromunda sıkça görülen bir metabolik bozukluk olan hiperüriseminin standart tedavisi hidrasyon, alkalinizasyon ve allopürinol uygulamasından oluşmaktadır. Rasbürikaz, ürik asitin idrarla kolaylıkla atılabilen bir metabolit olan allantoine etkin bir şekilde okside edilmesini sağlayan, rekombinant bir ürat oxidazdır. 37. gebelik haftasında sezaryen ile doğan hidrops fetalisli bir bebeği rapor etmeyi amaçladık. Anne kan grubu 0 Rh- negatif, bebek kan grubu ise 0, Rh-pozitif idi. İlk hemoglobin değeri 6.2 g/dl ve direkt Coombs +4’ti. Fizik muayenesinde multiorgan yetmezliği bulguları vardı. Yatışının 3. gününde bebekte oligüri gelişti; serum kreatinini 2.1 mg/dl’ ye ve ürik asit değeri de 23.7 mg/dl’ ye yükseldi. Allopürinol tedavisinden yanıt alınamayınca rasbürikaz tedavisi 0.2 mgr/kg dozunda başlandı. Dördüncü gün ürik asit düzeyi 13 mg/dl’ ye indi ve ikinci doz rasbürikaz tedavisi sonrası 5.gün ürik asit 2 mg/dl’ ye kadar düştü. Aynı dönemde başlanan devamlı furosemid infüzyonu sonrasında idrar çıkışı 1.5 ml/kg/st’ e kadar yükseldi. Hasta hayatının 10. gününde intrakranial kanama ve multiorgan yetmezliği nedeniyle kaybedildi. Bu vaka rasbürikaz tedavisi almış bilinen ilk hiperürisemik hidrops fetalis vakasıdır.

Anahtar Kelimeler: Hidrops Fetalis; Hiperürisemi; Rasbürikaz

References

  • Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11.
  • Harris JC. Disorders of Purine and Pyrimidine Metabolism. In:Kliegman RM, Behrman RE, editors. Nelson Textbook Of Pediatrics 19thed. Philadelphia, PA, USA:Elsevier Saunders; 2011. pp 516-517.
  • Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999;33:225-34.
  • Leusmann DB. A classification of urinary calculi with respect to their composition and micromorphology. Scand J Urol 1991;25:141–50.
  • Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences and treatment of tumor lysis syndrome. Am J Med 2004;116:546-54.
  • DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966;274:481-86.
  • Brogard JM, Coumaros D, Franckhauser J, Stahl A, Stahl J. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol 1972;17: 890-95.
  • Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21(23):4402-6.
  • Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B. et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19(3):697-704.
  • Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
  • Hobbs DJ, Steinke JM, Chung JY, Barletta GM, Bunchman TE. Rasburicase improves hyperuricemia in infants with acute kidney injury. Pediatr Nephrol 2010;25:305-9.
  • Murphy, JH. Nonimmune Hydrops Fetalis. NeoReviews 2004;5:e5-e14.
  • Bunchman TE, McBryde KD, Mottes TE, Gardner JJ, Maxvold NJ, Brophy PD. Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol 2001;16:1067-71.
  • Andreoli SP. Acute renal failure in the newborn. Semin Perinatol 2004;28:112-23.
  • Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk of kidney disease. J Am Soc Nephrol 2008;19:2407-13.
  • LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY, Moritz ML. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007;22:132-35.
  • Maisels MJ. Jaundice. In: S. M. MacDonald MG, Avery's Neonatology. 6thed. Lippincott Williams & Wilkins; 2005. pp: 768-90.
There are 17 citations in total.

Details

Journal Section Articles
Authors

YEŞİM Coşkun This is me

İpek Akman This is me

UTKU Demirel This is me

Publication Date March 27, 2016
Submission Date March 27, 2016
Published in Issue Year 2016 Volume: 2 Issue: 1

Cite

APA Coşkun, Y., Akman, İ., & Demirel, U. (2016). Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant. Journal of Human Rhythm, 2(1).
AMA Coşkun Y, Akman İ, Demirel U. Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant. Journal of Human Rhythm. March 2016;2(1).
Chicago Coşkun, YEŞİM, İpek Akman, and UTKU Demirel. “Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant”. Journal of Human Rhythm 2, no. 1 (March 2016).
EndNote Coşkun Y, Akman İ, Demirel U (March 1, 2016) Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant. Journal of Human Rhythm 2 1
IEEE Y. Coşkun, İ. Akman, and U. Demirel, “Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant”, Journal of Human Rhythm, vol. 2, no. 1, 2016.
ISNAD Coşkun, YEŞİM et al. “Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant”. Journal of Human Rhythm 2/1 (March 2016).
JAMA Coşkun Y, Akman İ, Demirel U. Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant. Journal of Human Rhythm. 2016;2.
MLA Coşkun, YEŞİM et al. “Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant”. Journal of Human Rhythm, vol. 2, no. 1, 2016.
Vancouver Coşkun Y, Akman İ, Demirel U. Use Of Rasburicase In The Treatment of Hyperuricemia In A Hydropic Infant. Journal of Human Rhythm. 2016;2(1).